Comparison of partners-heart failure algorithm vs care alert in remote heart failure management

Table 1 Study population

Clinical characteristics of the study population
Age (yr)	70.3 ± 8.3
Male (%)	78.3
EF (%)	27.5 ± 6.5
Etiology post-ischemic DC (%)	63.2
Idiopathic DC (%)	33.7
Valvular DC (%)	2
Congenital DC (%)	1.1
NYHA II (%)	17.3
III (%)	78.6
IV (%)	4.1
Optimized pharmacological treatment (%)	63.21
Prevention: Primary (%)	73.7
Secondary (%)	18.3
SVT (%)	3.7
Syncope (%)	3.2
Cardiac arrest (%)	5.1
AF permanent (%)	16.3
Persistent (%)	7.4
Paroxysmal (%)	4.1
Devices: Consulta™ CRT-D	37.4
Concerto™ II CRT-D (%)	26.3
Viva XT™ CRT-D (%)	22.1
Protecta XT™ CRT-D (%)	14.2

¹The low percentage of optimized pharmacological treatment is related to reduce aldosterone antagonists administration in patients affected by chronic kidney disease. EF: Ejection fraction; DC: Dilated cardiomyopathy; NYHA: New York Heart Association; SVT: Sustained ventricular tachycardia; AF: Atrial fibrillation; CRT-D: Cardiac resynchronization therapy-defibrillator.